Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial

Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial

Background Pneumococcal diseases among children aged <5 years worldwide are associated with high annual mortality rates. Purpose This study aimed to evaluate the immunogenicity and safety of GBP411, a 12-valent pneumococcal conjugant vaccine, with a dosing schedule of 2 primary doses plus 1 boost...

Full description

Bibliographic Details
Main Authors: Jonghoon Shin, Jamaree Teeratakulpisarn, Thanyawee Puthanakit, Tuangtip Theerawit, Ji Hwa Ryu, Jinhwan Shin, Seulgi Lee, Hayoung Lee, Kyungjun An, Hun Kim
Format: Article
Language:English
Published: The Korean Pediatric Society 2020-07-01
Series:Clinical and Experimental Pediatrics
Subjects:
12-valent pneumococcal conjugate vaccine
immunogenicity
safety
infant
Online Access:http://www.e-cep.org/upload/pdf/cep-2019-01067.pdf

Internet

http://www.e-cep.org/upload/pdf/cep-2019-01067.pdf

Similar Items